{{Rsnum
|rsid=11676382
|Gene=GGCX
|Chromosome=2
|position=85550510
|Orientation=plus
|GMAF=0.03719
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=GGCX
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 78.5 | 20.0 | 1.5
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 100.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|17764537}} [[rs11676382]] was associated with a [[warfarin]] maintenance dose across all analysis methods. the effects of GGCX are potentially population/treatment-dependent and will not have broad utility for determining [[warfarin]] dosing.

{{PMID Auto
|PMID=20694283
|Title=Gamma-glutamyl carboxylase and its influence on warfarin dose
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}